Rukobia Coupon & Prices
Complete a free online enrollment application to find out if you’re eligible to pay only $49 per month for your Rukobia medication with our help.Get Started Now
Secure: Your personal and medical information is safe with us
Convenient: Your medication is delivered straight to your door
Ongoing refills: Your medication is refilled automatically
Secure: Your personal and medical information is safe with us
Convenient: We manage the whole process and we’re here to assist you
Ongoing refills: We request your medication refills on your behalf
NiceRx works with your healthcare provider to help you access affordable medications directly from U.S. pharmaceutical companies.
How it works
Get started by filling out the online enrollment application to find out if you are eligible for assistance.
NiceRx verifies your eligibility for medication assistance and notifies you if you are pre-qualified. The pharmaceutical company provides your medication for free, and you only pay our service fee.
We will request documents to be submitted by you and your healthcare provider that are required by the pharmaceutical company to complete your enrollment.
Once approved, the pharmaceutical company typically ships a 90-day supply of medication to your home or healthcare provider’s address. Final acceptance is determined by the pharmaceutical company.
Your monthly Rukobia cost savings if eligible
With our assistance, you could access the Rukobia patient assistance program and obtain your medication for free. We only charge a flat monthly fee of $49 per medication for our services.
Am I eligible for Rukobia patient assistance?
We review each Rukobia enrollment application individually to determine if you are eligible. Each assistance program has its own eligibility criteria and the factors considered by most programs are:
- I am a permanent, legal resident of the United States or Puerto Rico
- I am uninsured or my insurance doesn’t cover my medication
- I meet certain income eligibility requirements
How do I apply for the Rukobia patient assistance program?
Our process makes it as easy as possible to apply for the Rukobia patient assistance program. Begin by completing the enrollment application form on our website. Tell us about any medications that you are taking, including Rukobia, your healthcare provider, your insurance plan, and your household income. This information is required by the pharmaceutical manufacturers who will supply the medication, so it is important to make sure this information is accurate and up to date.
We will review the information that you have provided to determine whether you are eligible for patient assistance. If we can pre-qualify you for assistance, NiceRx will handle the full enrollment process on your behalf. If you are approved by the pharmaceutical company, you will typically start receiving your medication in 6 – 8 weeks.
Is NiceRx a Rukobia coupons provider?
NiceRx is not a Rukobia coupon, Rukobia discount card, or Rukobia copay card provider. We do not offer Rukobia manufacturer coupons, Rukobia discounts, rebates, Rukobia savings cards, trial offers, or free Rukobia samples. We are a service provider that helps eligible individuals access their medication directly from the U.S. pharmaceutical company.
Can NiceRx help me if I have insurance?
NiceRx may be able to help you if:
- You have a high copay or coinsurance responsibility for Rukobia
- Your insurance company will not pay for your Rukobia prescription
- Your healthcare plan does not cover your medication
- You do not have insurance
Please apply online to find out if we can help you.
How much does Rukobia cost without insurance?
Without insurance, Rukobia costs will vary depending on where you buy the medication as prices will vary by retailer. As a guide, Rukobia oral tablets, extended-release 600 mg, will cost around $8,000 for 60 tablets.
How much does Rukobia cost with insurance?
The copay for Rukobia will depend on the terms of your healthcare plan. Your healthcare provider or pharmacist will be able to calculate your copay with your current insurance. Contact them to find out more.
What is Rukobia?
Rukobia is an FDA (U.S. Food and Drug Administration) approved medication manufactured by ViiV Healthcare. Approval was supported by data from the phase III Brighte study.
Rukobia is a human immunodeficiency virus type 1 (HIV-1) gp120-directed attachment inhibitor. It is used in combination with optimized background therapy (OBT), for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations.
Rukobia does not cure HIV-1 infection or AIDS, but it may delay damage to the immune system and the development of infections and diseases associated with AIDS. Rukobia is shown to help decrease viral load in some people whose virus is still detectable even after having exhausted many other treatment options.
What doses of Rukobia are available?
Rukobia is available in Extended-release tablet form, in the following doses: 600 mg.
One 600 mg tablet is taken twice daily with or without food. See the full prescribing information for a complete list of significant drug interactions. Always speak with your healthcare provider about any changes to your dose so they can monitor and evaluate your condition.
Rukobia active ingredients
The active ingredient of Rukobia is fostemsavir an HIV-1 antiretroviral (ARV) agent. Fostemsavirs mechanism of action is a prodrug without significant biochemical or antiviral activity. It is hydrolyzed to the active form temsavir, which is an HIV-1 attachment inhibitor. Temsavir binds directly to the gp120 subunit within the HIV-1 envelope glycoprotein gp160 and selectively inhibits the interaction between the virus with cellular CD4 receptors and T-cells. Temsavir also inhibits gp120-dependent post-attachment steps required for viral entry into host cells.
Rukobia side effects
The most common adverse reaction of Rukobia in clinical trials include:
In rare instances, Rukobia can cause more serious adverse events. These can include:
- Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapies
- QTc prolongation – treat with caution in patients with a history of QTc prolongation or with pre-existing cardiac disease or who are taking drugs with a known risk of Torsade de Pointes
- Elevations in hepatic transaminases in patients with hepatitis B or C virus co-infection. This was seen in a higher proportion in subjects with HBV and/or HCV co-infection compared to those with HIV mono-infection
Your doctor will assess the benefits of using Rukobia against your risk of side effects. Patients are encouraged to report negative side effects or adverse reactions of Rukobia to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Rukobia drug interactions
Rukobia can interact with other medications. These include:
- Oral contraceptives should not contain more than 30 mcg of ethinylestradiol per day
- Carbamazepine, Phenytoin
- St John’s wort (Hypericum perforatum)
- Grazoprevir, voxilaprevir plasma concentrations may be increased. Use an alternative hepatitis C virus treatment if possible
- Statins – atorvastatin fluvastatin pitavastatin simvastatin
This list is not exhaustive and other prescription drugs may interact with Rukobia. Tell your healthcare provider about all the medicines you take, including prescription drugs and over-the-counter medicines, vitamins, and herbal supplements.
You should not use Rukobia if you:
- Are allergic to the active ingredient fostemsavir
- Are allergic to any of the other ingredients in Rukobia
- Are taking strong cytochrome P450 (CYP)3A inducers as significant decreases in temsavir plasma concentrations may occur, which may result in loss of virologic response
Talk to your doctor before using Rukobia if you:
- Are taking any of the medications that could interact with Rukobia
- Are pregnant or are planning to become pregnant
- Are breastfeeding or are planning to breastfeed
- Have or have had a heart problem, including a heart rhythm problem called QTc prolongation
- Have or have had liver problems, including hepatitis B or C virus infection
Rukobia is the trademark brand name for fostemsavir manufactured by ViiV Healthcare. A generic version of fostemsavir is not available. Generic drugs are generally cheaper than brand-name drugs, but you can still find Rukobia savings through NiceRx.
*Qualifying persons may obtain medications directly from patient assistance programs without any out-of-pocket cost (or for less than $49 per medication). However, our monthly flat rate of just $49 per medication spares you the hassle of tracking the different programs and filling out all the required paperwork for each program. Subject to medication availability and acceptance by the pharmaceutical companies. NiceRx is not responsible for any delays or rejection by the pharmaceutical companies.
Enrollees enjoy a full-service solution, as NiceRx assists them and their physicians with the entire process. We prepare all required documents for the physician to sign, help enrollees manage all prescription refills, monitor eligibility criteria, and maintain enrollment.
**If you do not receive medications because you were determined to be ineligible for the prescription assistance by the applicable pharmaceutical companies and you have a letter of denial, we will refund any fees you paid toward medications for which you did not qualify to receive prescription assistance (“Refund”).
To receive a refund, you must send the letter of denial to us by fax to 888-517-7444, or by e-mail to [email protected] within 30 days of your receipt of such letter. The Refund is your sole and exclusive remedy for any fees you may wish to dispute.
The content on this website is intended for information purposes only. It does not constitute medical advice. The information on this website should not be relied upon and is not a substitute for professional medical advice. You should always speak to your doctor regarding the risks and benefits of any treatment.